Boston Private Wealth LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,938 shares of the medical research company’s stock after buying an additional 149 shares during the period. Boston Private Wealth LLC’s holdings in Thermo Fisher Scientific were worth $1,147,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. JJJ Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $25,000. Ellevest Inc. increased its stake in shares of Thermo Fisher Scientific by 137.5% during the second quarter. Ellevest Inc. now owns 95 shares of the medical research company’s stock worth $28,000 after purchasing an additional 55 shares in the last quarter. American National Bank purchased a new stake in shares of Thermo Fisher Scientific during the third quarter worth about $29,000. Massey Quick Simon & CO. LLC purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $30,000. Finally, Redhawk Wealth Advisors Inc. purchased a new stake in shares of Thermo Fisher Scientific during the second quarter worth about $31,000. 88.24% of the stock is owned by institutional investors.
A number of research firms have recently commented on TMO. JPMorgan Chase & Co. boosted their target price on shares of Thermo Fisher Scientific from $315.00 to $330.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Needham & Company LLC boosted their price target on shares of Thermo Fisher Scientific from $315.00 to $321.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Barclays set a $330.00 price target on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a research report on Monday, July 15th. Finally, Credit Suisse Group restated a “buy” rating and set a $310.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $314.45.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 2,271 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $298.00, for a total value of $676,758.00. Following the transaction, the chief executive officer now directly owns 283,502 shares in the company, valued at approximately $84,483,596. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 47,729 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $295.88, for a total transaction of $14,122,056.52. Following the completion of the transaction, the chief executive officer now owns 328,960 shares in the company, valued at $97,332,684.80. The disclosure for this sale can be found here. Insiders sold a total of 51,833 shares of company stock worth $15,299,095 over the last quarter. 0.45% of the stock is currently owned by company insiders.
NYSE:TMO traded up $0.08 on Friday, hitting $293.62. The stock had a trading volume of 320,255 shares, compared to its average volume of 1,323,858. The company has a quick ratio of 1.23, a current ratio of 1.80 and a debt-to-equity ratio of 0.56. The stock has a market cap of $117.34 billion, a price-to-earnings ratio of 26.40, a PEG ratio of 1.90 and a beta of 1.14. The company has a fifty day moving average price of $290.18 and a two-hundred day moving average price of $283.40. Thermo Fisher Scientific Inc. has a 1-year low of $208.34 and a 1-year high of $306.00.
Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, October 23rd. The medical research company reported $2.94 earnings per share for the quarter, beating the consensus estimate of $2.88 by $0.06. The company had revenue of $6.27 billion for the quarter, compared to analyst estimates of $6.19 billion. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.16%. Thermo Fisher Scientific’s revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the business posted $2.62 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 12.33 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 17th will be issued a $0.19 dividend. This represents a $0.76 annualized dividend and a yield of 0.26%. Thermo Fisher Scientific’s payout ratio is 6.83%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Further Reading: Most Volatile Stocks – What Investors Need to Know to Maximize ROI
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.